<DOC>
	<DOCNO>NCT00201773</DOCNO>
	<brief_summary>To test whether addition COX-2 inhibitor , celecoxib , decrease gene expression CYP19 breast cancer collect postmenopausal woman receive neoadjuvant exemestane .</brief_summary>
	<brief_title>Exemestane With Celecoxib Neoadjuvant Treatment Postmenopausal Women With Stage II , III , IV Breast Cancer</brief_title>
	<detailed_description>Rationale : In postmenopausal woman , main source estrogen conversion androgen , sex hormone produce adrenal gland . An enzyme call aromatase carry process . Exemestane , aromatase inhibitor , block production estrogen . Research indicate gene responsible aromatase activity CYPO19 . Therefore , exemestane help inhibit aromatase activity CYP019 . Along CYP019 , another gene associate breast cancer overexpression COX-2 enzyme . Research suggest COX-2 overexpression cause cancer cell division , increase blood flow tumor , metastasis . Celecoxib block COX-2 activity produce few side effect compare non-steroidal inflammatory drug ( NSAIDs ) . This study build previous research test combination exemestane celecoxib breast cancer . Purpose : This study evaluate safety efficacy exemestane celecoxib surgery stage II , III , IV breast cancer postmenopausal woman . Tests analyze CYP019 gene treatment . Treatment : Patients study receive exemestane celecoxib . Both drug give patient oral pill . Exemestane take daily sixteen week . Starting week 9 , celecoxib take twice daily eight week . Therefore , week 9-16 , patient take exemestane celecoxib . Several test exams give throughout study closely monitor patient , include biopsy perform first 8 week exemestane . After sixteen week exemestane celecoxib , patient breast surgery .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Must female histologically confirm breast cancer Stage IIIV disease ER and/or PR positive ECOG Performance Status 01 Tumor must present follow core needle biopsy determine physical exam radiographic evaluation . Postmenopausal No prior treatment current breast cancer . No active malignancy allowed.Adequately treat basal cell , squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree 5 year permit . Biphosphonates palliative radiation bone metastasis permit study . Hormone replacement therapy must discontinue . It permit time study . Known history aspirin NSAID induce asthma , urticaria allergic reaction ; allergy sulfonamide severe enough nature require emergency room treatment hospitalization . History myocardial infarction thrombotic event . Inflammatory breast cancer ( edema ulceration skin breast ) . Significant renal dysfunction ( serum creatinine &gt; 1.5 x upper limit normal ) . Significant hepatic dysfunction ( serum bilirubin &gt; 1.5 x upper limit normal AST , ALT &gt; 3 x upper limit normal ) ANC &lt; 1.5 , platelet &lt; 100,000 K/uL , hemoglobin &lt; 9 g/dL . Use COX2 inhibitor rofecoxib ( Vioxx® , aspirin , trisalicylate ( Trilisate® ) , permit time study . No washout period require . Baby aspirin , 81 mg po daily , permit . Use NSAID 's ibuprofen ( Advil® Motrin® ) , naproxyn ( Aleve® Naprosyn® , Anaprox® ) , etodolac ( Lodine® ) , oxaprozin ( Daypro® ) , difusanil ( Dolobid® ) , nabumetone ( Relafin® ) , tolmetin ( Tolectin® ) permit time study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Post-Menopause</keyword>
	<keyword>Neoadjuvant Therapy</keyword>
</DOC>